|
Calfactant
Calfactant (Infasurf)
Calfactant
(kal-FAK-tant)
Infasurf (Rx)
Classification:
Lung surfactant
Action/Kinetics:
Lung surfactant which contains phospholipids, neutral lipids, and hydrophobic surfactant-associated proteins B and C from calf lungs. Calfactant modifies alveolar surface tension thus stabilizing alveoli. Adsorbs rapidly to the surface of the air:liquid interface and modifies surface tension similarly to natural lung surfactant. Treatment often rapidly improves oxygenation and lung compliance.
Uses:
Prevention and treatment of respiratory distress syndrome in premature infants.
Special Concerns:
For endotracheal use only. An increased proportion of clients with both intraventricular hemorrhage and periventricular leukomalacia may be seen. These were not associated with increased mortality.
Side Effects:
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into the endotracheal tube, requirement for manual ventilation, reintubation.
How Supplied:
Suspension, intratracheal: 35 mg phospholipids/mL
Dosage
•Intratracheal suspension
Prophylaxis of respiratory distress syndrome at birth.
Instill 3 mL/kg of birth weight as soon as possible after birth. Give as 2 doses of 1.5 mL/kg each. Care and stabilization of the premature infant born with hypoxemia or bradycardia should precede calfactant therapy.
Treatment of respiratory distress syndrome within 72 hr of birth.
Instill 3 mL/kg of birth weight, given as 2 doses of 1.5 mL/kg. Repeat doses of 3 mL/kg of birth weight may be given, up to a total of 3 doses 12 hr apart. |
Discuss prescriptions and health topics in the new 